What is CUCART19 used for?

CUCART19 is indicated for Prevention of COVID-19.

CUCART19 is developed by Chi Kong Li.

What are the side effects of CUCART19?

Common side effects include Injection site pain.

Last reviewed 2026-04-23 · How we verify

CUCART19

Chi Kong Li · Phase 2 active Small molecule

CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein.

CUCART19 is a monoclonal antibody targeting the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.

At a glance

Generic name	CUCART19
Also known as	anti-CD19 CAR-T
Sponsor	Chi Kong Li
Drug class	Monoclonal antibody
Target	SARS-CoV-2 spike protein
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

CUCART19 works by binding to the spike protein of the SARS-CoV-2 virus, preventing it from entering host cells and thereby inhibiting viral replication.

Approved indications

Prevention of COVID-19

Common side effects

Injection site pain

Key clinical trials

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CUCART19 CI brief — competitive landscape report
CUCART19 updates RSS · CI watch RSS
Chi Kong Li portfolio CI